DiaMedica Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $342.1M
- Price
- $6.57
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.77%
- Volume
- 51.7K
About
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Quick stats
Shares outstanding52.1M
Computed float24.3M
Float / shares46.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001401040
Websitehttps://www.diamedica.com
AI Summary
AI-generated1/22
standardbullishearnings
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
DiaMedica reported Q2 financial results with $43.5 million in cash and investments, providing a runway to fund operations through 2027, while recording a net loss of $10.1 million for the quarter.
The company announced positive topline results from the Phase 2 late-onset preeclampsia study, showing a statistically significant mean reduction of 29.1 mmHg in systolic blood pressure.
Clinical progress continues across the pipeline, with enrollment in the acute ischemic stroke ReMEDy2 trial surpassing 85% and the first cohort of the fetal growth restriction trial completing enrollment.
Red flags
- FDA indicated that an additional rat pharmacokinetic and pharmacologic activity study is required to support IND clearance for preeclampsia
- Cash position decreased by $16.4 million in six months